Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 3/20 | 0.57 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.53 |
| ▸ | AURKA | O14965 | 2/20 | 0.32 |
| ▸ | CDK2 | P24941 | 2/20 | 0.32 |
| ▸ | CDK9 | P50750 | 2/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | CDK7 | P50613 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | CDK4 | P11802 | 1/20 | 0.31 |
| ▸ | WEE1 | P30291 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3926829 | 0.91 | CRHR1 (0.55) | CRHR1CRHR2 | |
| SCHEMBL3932532 | 0.90 | CRHR1 (0.54) | CRHR1CRHR2 | |
| SCHEMBL3925880 | 0.90 | CRHR1 (0.58) | CRHR1CRHR2CDK2CDK9CDK1 | |
| SCHEMBL3935105 | 0.89 | CRHR1 (0.53) | CRHR1CRHR2CDK2CDK4 | |
| SCHEMBL3926385 | 0.89 | CRHR1 (0.57) | CRHR1CRHR2 | |
| SCHEMBL3921424 | 0.88 | CRHR1 (0.56) | CRHR1CRHR2 | |
| SCHEMBL3932242 | 0.88 | CRHR1 (0.56) | CRHR1CRHR2CDK2CDK9CDK1 | |
| SCHEMBL3930746 | 0.88 | CRHR1 (0.52) | CRHR1CRHR2 | |
| SCHEMBL3926815 | 0.88 | CRHR1 (0.52) | CRHR1CRHR2 | |
| SCHEMBL3923659 | 0.88 | CRHR1 (0.52) | CRHR1CRHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612067-B2 | Imidazopyridazine compounds | ELI LILLY AND COMPANY (US) | 2009-11-03 | — | — | US | disclosed |
| US-7612067-B2 | Imidazopyridazine compounds | ELI LILLY AND COMPANY (US) | 2009-11-03 | — | — | US | disclosed |
| US-20080113978-A1 | Imidazopyridazine Compounds | ELI LILLY AND COMPANY | 2008-05-15 | — | — | US | disclosed |
| US-20080113978-A1 | Imidazopyridazine Compounds | ELI LILLY AND COMPANY | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113978-A1 | Imidazopyridazine Compounds | CRHR1, CRH, CRHR2 | CRHR1 1/4885CRHR2 3/4885AURKA 4136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.